Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B₁₆ bearing mice

References

• Amadori D, Carrasco E, Roesel S, et al. (2013). A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients. Int J Oncol 42:1778–85
   PubMed Web of Science ®Google Scholar
• Argiris A, Karamouzis MV, Gooding WE, et al. (2011). Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 29:1140–5
   PubMed Web of Science ®Google Scholar
• Bai J, Zhang J, Wu J, et al. (2010). JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 29:1227–37
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–206
   PubMed Web of Science ®Google Scholar
• Becker KF, Kremmer E, Eulitz M, et al. (1999). Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody. Am J Pathol 155:1803–9
   PubMed Web of Science ®Google Scholar
• Berx G, Van Roy F. (2001). The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3:289–93
   PubMed Web of Science ®Google Scholar
• Berx G, Cleton-Jansen AM, Nollet F, et al. (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107–15
   PubMed Web of Science ®Google Scholar
• Braeuer RR, Watson IR, Wu CJ, et al. (2014). Why is melanoma so metastatic? Pigment Cell Melanoma Res 27:19–36
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Rosemurgy A, Brown PD, et al. (2001). Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19:3447–55
   PubMed Web of Science ®Google Scholar
• Brown PD. (2000). Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 9:2167–77
   PubMed Web of Science ®Google Scholar
• Cameron MD, Schmidt EE, Kerkvliet N, et al. (2000). Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 60:2541–6
   PubMed Web of Science ®Google Scholar
• Carneiro F, Machado JC, Seruca R, et al. (1999). E-cadherin changes in gastric carcimona. Histopathology 35:477–8
   PubMed Web of Science ®Google Scholar
• Chambers SK, Chow HH, Janicek MF, et al. (2012). Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res 18:2668–78
   PubMed Web of Science ®Google Scholar
• Chen, ZG. (2010). Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med 16:594–602
   PubMed Web of Science ®Google Scholar
• Coussens LM, Fingleton B, Matrisian LM. (2002). Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–92
   PubMed Web of Science ®Google Scholar
• Cui FB, Li RT, Liu Q, et al. (2014a). Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer. Cancer Lett 346:53–62
   PubMed Web of Science ®Google Scholar
• Cui FB, Liu Q, Li RT, et al. (2014b). Enhancement of radiotherapy efficacy by miR-200c-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer cells. Int J Nanomed 9:2345–58
   PubMed Web of Science ®Google Scholar
• Fidler IJ. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–8
   PubMed Web of Science ®Google Scholar
• Fokas E, Engenhar-Cabillic R, Daniilidis K, et al. (2007). Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev 26:705–15
   PubMed Web of Science ®Google Scholar
• Gialeli C, Theocharis AD, Karamanos NK. (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278:16–27
   PubMed Web of Science ®Google Scholar
• Hirohashi S. (1998). Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153:333–9
   PubMed Web of Science ®Google Scholar
• Hughes A, Calvert P, Azzabi A, et al. (2002). Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533–44
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Rafii S, Lyden D. (2006). Preparing the “soil”: the premetastatic niche. Cancer Res 66:11089–93
   PubMed Web of Science ®Google Scholar
• Kin JH, Park JM, Jung CW, et al. (2008). The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma. J Surg Oncol 97:125–30
   PubMed Web of Science ®Google Scholar
• Langley RR, Fidler IJ. (2011). The seed and soil hypothesis revisited – the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128:2527–35
   PubMed Web of Science ®Google Scholar
• Li R, Li X, Xie L, et al. (2009). Preparation and evaluation of PEG-PCL nanoparticles for local tetradrine delivery. Int J Pharm 379:158–66
   PubMed Web of Science ®Google Scholar
• Li R, Wu W, Liu Q, et al. (2013). Intelligently targeted drug delivery and enhanced antitumor effect by gelatinase-responsive nanoparticles. PLoS One 30:8
   Google Scholar
• Liu Q, Li R, Qian H, et al. (2012). Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles. Int J Nanomed 7:281–95
   PubMed Web of Science ®Google Scholar
• Liu Q, Li R, Qian H, et al. (2013). Targeted de livery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. Biomaterials 34:7191–203
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–8
   PubMed Web of Science ®Google Scholar
• Lu N, Liu Q, Li R, et al. (2012). Superior antimetastatic effect of pemetrexed-loaded gelatinase-responsive nanoparticles in a mouse metastasis model. Anticancer Drugs 23:1078–88
   PubMed Web of Science ®Google Scholar
• Luzzi KJ, MacDonald IC, Schmidt EE, et al. (1998). Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 153:865–73
   PubMed Web of Science ®Google Scholar
• Mahler-Araujo B, Savage K, Parry S, et al. (2008). Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 61:615–20
   PubMed Web of Science ®Google Scholar
• Manegold C, Gatzmeier U, von Pawel J, et al. (2000). Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 11:435–40
   PubMed Web of Science ®Google Scholar
• Miles DW, Smith IE, Coleman RE, et al. (2001). A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 37:1366–71
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Ramondetta LM, et al. (2014). Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol 32:2744–9
   PubMed Web of Science ®Google Scholar
• Pinheiro H, Bordeira-Carriço R, Seixas S, et al. (2010). Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 19:943–52
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Cancela Paredes J, Milanezi F, et al. (2002). Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 94:2114–15
   PubMed Web of Science ®Google Scholar
• Saad AA, Awed NM, Abd Elierim NN, et al. (2010). Prognostic significance of E-cadherin expression and peripheral blood micrometastasis in gastric carcinoma patients. Ann Surg Oncol 17:3059–67
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Marmé F, Ruiz A, et al. (2011). A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. Ann Oncol 22:609–17
   PubMed Web of Science ®Google Scholar
• Specht K, Richter T, Müller U, et al. (2001). Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158:419–29
   PubMed Web of Science ®Google Scholar
• Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 20. 2:442–54
   Web of Science ®Google Scholar
• Wu FL, Li RT, Yang M, et al. (2015). Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2′-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics. Cancer Lett doi: 10.1016/j.canlet.2015.01.006
   Web of Science ®Google Scholar
• Zhang DS, Jin Y, Luo HY, et al. (2015). Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study. Br J Cancer 112:266–70
   PubMed Web of Science ®Google Scholar